The narrowing net loss and strong cash runway into 2028 reduce near-term dilution risk. However, the absence of recurring collaboration revenue and reliance on future clinical data (2026) make the stock sensitive to trial outcomes. Traders should monitor upcoming 2026 data readouts from vopimetostat combination trials as key catalysts.
Price Chart
Executive Summary
Tango Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $343.1 million, reduced net losses year-over-year, and advancing its vopimetostat clinical program in pancreatic cancer. The company initiated a clinical supply agreement with Erasca and continues enrollment in combination trials with Revolution Medicines, with initial data expected in 2026. Leadership changes include CEO succession and expanded regulatory leadership.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities totaled $343.1 million as of December 31, 2025, providing runway into 2028.
- Collaboration revenue dropped to $0 in Q4 2025 from $5.4 million in Q4 2024; full-year 2025 collaboration revenue was $62.4 million vs. $30.0 million in 2024, driven by recognition of deferred revenue from Gilead.
- Net loss narrowed to $101.6 million in 2025 from $130.3 million in 2024; Q4 2025 net loss was $38.7 million vs. $30.8 million in Q4 2024.
- Vopimetostat pivotal study in 2L pancreatic cancer expected to start in 2026; initial combination data with RAS(ON) inhibitors anticipated in 2026.
- CEO transition completed: Dr. Malte Peters succeeded founding CEO Dr. Barbara Weber, who became Executive Chair through 2026.
Financial Impact
Revenue declined sharply in Q4 2025 due to absence of collaboration income, but full-year revenue more than doubled due to one-time Gilead revenue recognition. R&D expenses decreased year-over-year due to discontinuation of TNG908 and TNG348 programs, contributing to improved net loss profile.
Risk Factors
- Revenue is non-recurring and heavily reliant on past Gilead collaboration; no new major partnerships announced.
- Clinical execution risk: pivotal trial initiation and data readouts are forward-looking and subject to delay.
- Recent insider selling ($694K in 30 days) may signal caution among executives.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250000 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.33 (+8.78%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.33 (−11.41%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.33 (−11.41%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.33 (−15.67%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.33 (−13.80%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.33 (−24.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access